Arrowhead Pharmaceuticals, Inc. ARWR
65.92
(0.15)
(0.23%)
as of 25 Sep
- Market cap
- $9.3B
- P/E
- 0.0×
Follow ARWR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (64.91%) | (46.90%) | 65.38% | (0.47%) |
+8 more TTM periods Free account |
|
| (18.32%) | (15.67%) | 15.45% | (0.13%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(18.16%) | (15.68%) | 16.78% | (0.14%) | |
Average Days of Receivables |
4.66 | 9.20 | 73.23 | 3.00 | |
Free Cash Flow per Share |
(0.52) | (0.36) | 2.35 | 1.17 | |
Free Cash Flow |
(75.11) | (50.87) | 322.01 | 156.89 | |
Capital Expenditures |
(16.06) | (14.57) | (17.30) | (22.67) | |
Piotroski F-Score |
2.00 | 2.00 | 6.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(2.01%) | (1.11%) | 20.17% | 10.70% | |
Accounts Receivable Turnover |
73.35 | 68.92 | 9.86 | 205.54 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.08 | 0.08 | (0.08) | (0.42) | |
Research and Development Expense of Revenue |
108.05% | 110.53% | 59.34% | 73.20% | |
Selling, General and Administrative Expense of Revenue |
25.78% | 25.14% | 13.11% | 14.94% | |
Share Based Compensation of Revenue |
10.46% | 10.96% | 6.19% | 7.64% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.18 | 0.12 | 1.68 | (110.09) | |
Depreciation/Fixed assets |
0.06 | 0.05 | 0.05 | 0.05 | |
Capex/Depreciation |
(0.73) | (0.71) | (0.90) | (1.25) | |
Revenue per Share |
4.67 | 4.37 | 7.96 | 6.20 | |
Operating CF per Share |
(0.41) | (0.25) | 2.48 | 1.34 | |
Capex per Share |
(0.11) | (0.10) | (0.13) | (0.17) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.03 | |
Net Profit Margin |
(47.79%) | (48.38%) | 18.54% | (0.20%) |
Columns are period end dates